Mendus AB is a clinical-level biopharmaceutical company, which engages in the provision of allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. It operates under the Sweden and Netherlands geographic segments. The company was founded by Bengt Anders Andersson, Alex Karlsson-Parra, and AnnaCarin Wallgren in 2002 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company